Quick Answer
Sensei Biotherapeutics, Inc. reported Net Income of -$21.09 million for fiscal year 2025.
Sensei Biotherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$21.09M +30.1% |
-$30.16M +11.6% |
-$34.10M +29.8% |
-$48.59M -32.1% |
-$36.79M -83.1% |
-$20.10M |
| Diluted EPS | -$16.72 +30.4% |
-$24.01 -1868.0% |
-$1.22 +22.8% |
-$1.58 -18.8% |
-$1.33 | — |
| Total Assets | $22.90M -49.5% |
$45.36M -39.0% |
$74.37M -37.2% |
$118.38M -22.7% |
$153.22M +615.1% |
$21.43M |
| Cash and Equivalents | $8.67M -13.3% |
$9.99M -23.2% |
$13.01M -26.9% |
$17.80M +148.6% |
$7.16M -56.9% |
$16.60M |
| Long-Term Debt | — | — | — | — | — | $567.0K |
| Stockholders Equity | $18.59M -51.6% |
$38.39M -40.8% |
$64.89M -37.2% |
$103.41M -29.4% |
$146.51M +359.6% |
-$56.44M +17.8% |
| Operating Income | -$22.29M +31.7% |
-$32.61M +12.0% |
-$37.06M +26.1% |
-$50.19M -33.9% |
-$37.48M -92.7% |
-$19.45M |
| Shares Outstanding | 1.26M +0.2% |
1.26M -95.0% |
25.03M -18.6% |
30.76M +0.5% |
30.61M +1532.1% |
1.88M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.57M | +37.0% | +7.4% |
| Diluted EPS | September 30, 2025 | -$3.62 | +37.3% | +7.4% |
| Total Assets | September 30, 2025 | $27.59M | -48.2% | -13.2% |
| Cash and Equivalents | September 30, 2025 | $10.56M | -44.8% | -15.9% |
| Long-Term Debt | June 30, 2021 | $567.0K | — | +0.0% |
| Stockholders Equity | September 30, 2025 | $23.01M | -49.7% | -15.8% |
| R&D Expense | March 31, 2021 | $3.37M | +53.3% | +53.3% |
| Operating Income | September 30, 2025 | -$4.85M | +38.0% | +6.8% |
| Shares Outstanding | September 30, 2025 | 1.26M | -95.0% | +0.0% |
- Sensei Biotherapeutics, Inc. reported Net Income of -$21.09 million for fiscal year 2025.
- Sensei Biotherapeutics, Inc. showed an increase of +30.1% in Net Income compared to the prior fiscal year.
- Sensei Biotherapeutics, Inc. reported Diluted EPS of $16.72 per share (loss) for fiscal year 2025.
- Sensei Biotherapeutics, Inc. showed an increase of +30.4% in Diluted EPS compared to the prior fiscal year.
- Sensei Biotherapeutics, Inc. reported Total Assets of $22.90 million for fiscal year 2025.
- Sensei Biotherapeutics, Inc. showed a decrease of -49.5% in Total Assets compared to the prior fiscal year.
- Sensei Biotherapeutics, Inc. reported Cash and Equivalents of $8.67 million for fiscal year 2025.
- Sensei Biotherapeutics, Inc. showed a decrease of -13.3% in Cash and Equivalents compared to the prior fiscal year.
- Sensei Biotherapeutics, Inc. reported Long-Term Debt of $567.0 thousand for fiscal year 2020.
- Sensei Biotherapeutics, Inc. reported Stockholders Equity of $18.59 million for fiscal year 2025.
- Sensei Biotherapeutics, Inc. showed a decrease of -51.6% in Stockholders Equity compared to the prior fiscal year.
- Sensei Biotherapeutics, Inc. reported Operating Income of -$22.29 million for fiscal year 2025.
- Sensei Biotherapeutics, Inc. showed an increase of +31.7% in Operating Income compared to the prior fiscal year.
- Sensei Biotherapeutics, Inc. reported Shares Outstanding of 1.26 million shares for fiscal year 2025.
- Sensei Biotherapeutics, Inc. showed an increase of +0.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: